Trials / Completed
CompletedNCT02939651
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
A Phase 2, Open-label Study of Pembrolizumab Monotherapy in Patients With Metastatic High Grade Neuroendocrine Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Fox Chase Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to test if pembrolizumab is safe and effective for treating patients with metastatic high-grade neuroendocrine tumors who have failed platinum based chemotherapy.The study drug, pembrolizumab has been FDA approved for treating a type of skin cancer called melanoma and for metastatic non-small cell lung cancer. However, it is not approved for treatment of metastatic high-grade neuroendocrine tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks |
Timeline
- Start date
- 2016-10-26
- Primary completion
- 2018-02-01
- Completion
- 2020-03-01
- First posted
- 2016-10-20
- Last updated
- 2021-03-09
- Results posted
- 2021-03-09
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02939651. Inclusion in this directory is not an endorsement.